Literature DB >> 2317862

The effects of MHC gene dosage and allelic variation on T cell receptor selection.

L J Berg1, G D Frank, M M Davis.   

Abstract

In a T cell receptor transgenic mouse model of thymic selection, the efficiency of selection of the transgenic alpha beta heterodimer is significantly enhanced in animals that express higher densities of the relevant major histocompatibility complex molecule (I-Ek/b). These results imply that there is a stochastic component to positive selection in the thymus. Allelic variants of the original selecting I-Ek molecule are either less efficient (E alpha k:E beta b) or incapable (E alpha k:E beta s and I-Ed) of mediating the selection of transgenic alpha beta + T cells. Two of these three I-E variants appear to differ from I-Ek in amino acid residues of the peptide binding site and not in residues capable of contacting the T cell receptor, suggesting that specific peptides, or conformations of peptides, play a role in positive selection. In contrast, mice transgenic for only the beta chain of this T cell receptor show selection for CD4+ T cells in the presence of all four I-E variants tested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317862     DOI: 10.1016/0092-8674(90)90352-f

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  28 in total

1.  Diversity of T cell repertoire shaped by a single peptide ligand is critically affected by its amino acid residue at a T cell receptor contact.

Authors:  Y Fukui; T Oono; J P Cabaniols; K Nakao; K Hirokawa; A Inayoshi; T Sanui; J Kanellopoulos; E Iwata; M Noda; M Katsuki; P Kourilsky; T Sasazuki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Positive selection of Tcrb-V4+CD8+ T cells by H-2d molecules.

Authors:  K Tomonari; S Fairchild
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

3.  Profound alteration in an alpha beta T-cell antigen receptor repertoire due to polymorphism in the first complementarity-determining region of the beta chain.

Authors:  S J Gahm; B J Fowlkes; S C Jameson; N R Gascoigne; M M Cotterman; O Kanagawa; R H Schwartz; L A Matis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

4.  Altered thymic positive selection and intracellular signals in Cbl-deficient mice.

Authors:  M Naramura; H K Kole; R J Hu; H Gu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Control of immunodeficiency and lymphoproliferation in mouse AIDS: studies of mice deficient in CD8+ T cells or perforin.

Authors:  Y Tang; A W Hügin; N A Giese; L Gabriele; S K Chattopadhyay; T N Fredrickson; D Kägi; J W Hartley; H C Morse
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 6.  The roles of MHC class II genes and post-translational modification in celiac disease.

Authors:  Ludvig M Sollid
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 2.846

7.  Defective selection of thymic regulatory T cells accompanies autoimmunity and pulmonary infiltrates in Tcra-deficient mice double transgenic for human La/Sjögren's syndrome-B and human La-specific TCR.

Authors:  Jane C Yaciuk; Yujun Pan; Karen Schwarz; Zi-Jian Pan; Jacen S Maier-Moore; Stanley D Kosanke; Christina Lawrence; A Darise Farris
Journal:  J Immunol       Date:  2015-01-12       Impact factor: 5.422

Review 8.  Regulatory T cells for tolerance therapy: revisiting the concept.

Authors:  Christian Leguern
Journal:  Crit Rev Immunol       Date:  2011       Impact factor: 2.214

9.  In search of TCR restriction in autoreactive T cell in human autoimmunity: why is it so elusive?

Authors:  C Navarrete; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

10.  Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice.

Authors:  C J Aldrich; H G Ljunggren; L Van Kaer; P G Ashton-Rickardt; S Tonegawa; J Forman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.